Talem Therapeutics

Talem Therapeutics Focuses on the Discovery and Development of Therapeutic Antibodies for Emerging Diseases, Infectious Diseases, Neurology, Immuno-Oncology, Inflammation, and Rare/Special DiseasesTalem Therapeutics (Talem), a wholly-owned subsidiary of ImmunoPrecise Antibodies (IPA), is dedicated to the discovery and development of next-generation fully human monoclonal therapeutic antibodies for various disease indications. By leveraging proprietary antibody discovery platforms and innovative technologies owned by ImmunoPrecise Antibodies and U-Protein Express, Talem is committed to accelerating the research and development of novel, high-value therapeutic antibodies for clinical use.